|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 45.14 USD | -0.35% |
|
-4.08% | -24.98% |
| Apr. 23 | Genscript Biotech Unit Gets Approval for Blood Cancer Drug by European Commission | MT |
| Apr. 22 | Legend Biotech's Carvykti Gets European Commission Approval for Treatment of Blood Cancer | MT |
April 5 (Reuters) - The U.S. Food and Drug Administration on Friday allowed the expanded use of Johnson & Johnson and Legend Biotech's Carvykti cell therapy as an earlier treatment for patients with a type of blood cancer. (Reporting by Disha Mishra in Bengaluru; Editing by William Mallard)
Price
|
Change
|
5d. change
|
Capi.
| ||
|---|---|---|---|---|---|
| 146.8 USD | +0.47% | -1.54% | 352B | ||
| 45.14 USD | -0.35% | -4.08% | 8.24B | ||
| 1st Jan change | Capi. | |
|---|---|---|
| -24.98% | 8.24B | |
| -2.63% | 103B | |
| +1.62% | 95.28B | |
| +1.46% | 22.15B | |
| -16.67% | 21.02B | |
| -8.58% | 18.15B | |
| -38.74% | 16.73B | |
| -13.21% | 16.05B | |
| +5.41% | 13.68B | |
| +33.57% | 12.17B |
LEGEND BIOTECH CORPORATION 
